Assessing the Performance of Daily Intake of a Homotaurine, Carnosine, Forskolin, Vitamin B2, Vitamin B6, and Magnesium Based Food Supplement for the Maintenance of Visual Function in Patients with Primary Open Angle Glaucoma

Background. Glaucoma is a multifactorial optic neuropathy, which causes a continuous loss of retinal ganglion cells. Given the neurodegenerative nature of glaucoma, the necessity for neuroprotective intervention still arises, to be added alongside hypotonic therapy. Objective. The objective of this...

Full description

Saved in:
Bibliographic Details
Published in:Journal of ophthalmology 2020, Vol.2020 (2020), p.1-9
Main Authors: Curto, Daniela, Rossatto, Stefania, Dallorto, Laura, Rolle, Teresa, Nuzzi, Raffaele
Format: Article
Language:English
Subjects:
Apoptosis
Care and treatment
Defects
Dietary supplements
Disease
Folic acid
Glaucoma
Medical research
Medicine, Experimental
Pathology
Patients
Studies
Vitamin B
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background. Glaucoma is a multifactorial optic neuropathy, which causes a continuous loss of retinal ganglion cells. Given the neurodegenerative nature of glaucoma, the necessity for neuroprotective intervention still arises, to be added alongside hypotonic therapy. Objective. The objective of this study was to assess the effect of daily intake of a homotaurine, carnosine, forskolin, vitamins B1, B2, and B6, folic acid, and magnesium based supplement (GANGLIOLIFE®) on the progression rates of the visual field in patients with progressive POAG despite good tonometric compensation and to assess the most suitable dosage. Methods. This is a monocentric nonrandomized experimental clinical study. Patients with mean deviation (MD) ranging from −2 dB to −15 dB with MD progression ≥1 dB in the previous year and IOP values of ≤18 mm Hg were included. All the patients underwent supplement therapy for a period of 6 months. For the first 2 months, they took 2 tablets a day, and for the following 4 months, 1 tablet a day. The patients were assessed before the start of treatment, time 0 (T0), after 2 months (T1), and after 6 months (T2) of therapy. At each check-up, patients were given a full eye test including perimetry, RNFL, and GCC using FD-OCT, PERG, contrast sensitivity, and QoL evaluation using the Glaucoma Symptom Scale questionnaire and National Eye Institute Visual Function Questionnaire 25. Results. 31 patients with a mean age of 70.80 ± 8.77 were included. At T1 and T2, the mean values of MD were lessened (MD = −5.37 ± −2.91, P
ISSN:2090-004X
2090-0058
DOI:10.1155/2020/7879436